Multimodal Imaging for Adrenal Tumor Characterization: Clinical Impact of the 2023 European Guidelines - A Single-Center Retrospective Study
Clicks: 1
ID: 329377
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #110 of 112 articles by views in european journal of endocrinology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Adrenal lesions are becoming increasingly common with the advent of abdominal imaging. Although mostly benign and nonfunctional, some cases may be malignant or secretory and justify adrenalectomy. The 2023 European guidelines propose a more conservative approach (focused on simple radiological criteria) to limit unnecessary surgery. However, the impact of this strategy on the management of malignant lesions remains to be assessed. Methods We conducted a single-center retrospective study including all patients who underwent adrenalectomy between 2017 and 2024. The aim was to investigate the potential impact of the new iconographic criteria of the 2023 European recommendations. Patients aged over 18 years with at least one preoperative imaging examination and a histopathology report were included. Results Among 259 patients, 75% had benign lesions, and 25% had malignant lesions. Based on the 2016 guidelines, 71% of the patients would have undergone surgery, whereas 31% would have undergone surgery according to the 2023 criteria. With respect to malignant lesions, 98% of the patients would have received surgery according to the 2016 criteria, whereas 60% would have received surgery according to the 2023 criteria. The inclusion of hypersecretion increased this rate to 93%, and the addition of complementary imaging ensured the detection of all malignant cases. Conclusion The 2023 guidelines may substantially reduce unnecessary adrenalectomies for benign lesions. The risk of missing malignant tumors remains low when hormonal evaluation and multimodal imaging (such as MRI and FDG-PET) are used, particularly in indeterminate cases.
| Reference Key |
openalex_W7213983183
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Esther Lutz, Timothée Zaragori, Claire Nominé-Criqui, Pierre-Yves Marie, Marc Klein, Nicolas Scheyer |
| Journal | european journal of endocrinology |
| Year | 2026 |
| DOI |
10.1093/ejendo/lvag179
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.